MedTrace Logo

Retrospective Study of Romiplostim for Platelet Engraftment After Allo-HSCT

NCT07747246 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 103

Last updated 2026-08-05

No results posted yet for this study

Summary

This is a retrospective observational study evaluating the efficacy and safety of romiplostim for promoting platelet engraftment in patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology between January 2025 to May 2026. Medical records were reviewed to collect data on platelet recovery time, transfusion requirements, and adverse events. The primary endpoint was time to platelet engraftment. Secondary endpoints included platelet recovery kinetics, transfusion requirements, transplant-related complications, and safety outcomes.No interventions were assigned as part of this study.

Conditions

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • wen · Tongji Hospital Affiliated to Tongji Medical College of Huaz- hong University of Science and Technology

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2026-05-01
Completion
2026-07-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07747246 on ClinicalTrials.gov